BUZZ-Australia's Orthocell surges on sales approval in Singapore
Reuters
Mar 18
BUZZ-Australia's Orthocell surges on sales approval in Singapore
** Shares of Orthocell OCC.AX rise 11% to A$1.52, hitting their highest levels since Feb 20
** The biotech firm receives regulatory approval from Singapore's Health Sciences authority to start sales of its Striate+ product
** Striate+ is a dental guided bone regeneration product
** Says co working with Striate+ distribution partner BioHorizons to fast-track expansion to other regions including Brazil
** Stock up ~11.1% YTD, including current session's moves
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.